flexiblefullpage -
billboard - default
interstitial1 - interstitial
Currently Reading

Bigger is better for a maturing life sciences sector


Bigger is better for a maturing life sciences sector

CRB's latest report predicts more diversification and vertical integration in research and production.

By John Caulfield, Senior Editor | October 5, 2022
Rendering of Rhode Island Life Sciences Building
A rendering of a proposed life sciences building in Providence, R.I., that would house a new state health lab, lab space for Brown University, and leasable biotech space. Image: Rhode Island Department of Administration

“While the COVID-19 pandemic taught new lessons about the quick and safe delivery of critical vaccines, the global shock is only now being understood.” That’s the opening observation of the 98-page 2022 Life Sciences Report, published by the AC firm CRB and based on responses from nearly 500 industry leaders, which explores this industry sector’s R&D and growth strategies.

This is CRB’s third Horizons report, and its first to include Europe, where many of the industry’s leading organizations are paving the way through innovation, groundbreaking research, and new and dynamic ways of speeding therapies to patients.

CRB is seeing a rapidly maturing industry that’s in pursuit of more diversification. “The days of single-product specialization are receding,” the report states, as companies large and small are utilizing a wide array of tools to expand their pipeline and address diverse indications.

Nearly all respondents (90%) are developing and manufacturing multiple therapy modalities in a single building, or plan to do so in the future. And more than half of the respondents plans to rely on contract development and manufacturing organizations (CDMOs) over the next three years. “We’re seeing a rise in hybrid models—that is, owners who are offering their in-house manufacturing expertise for hire,” the report states.

As such, the nature of in-demand talent is changing, as companies mature towards more automated, AI-driven manufacturing models, with the traditional C-suite expanding to include roles previously unseen in this industry, such as “Chief Data Officer.”


Growth average targets for life Science firms
Life science researchers and clinicians are anticipating robust annual growth and laboratory expansion. Chart credit: CRB

life science lab expansionCell therapies emerge as dynamic submarket

CRB divides its report into eight chapters, each with contextualized perspectives. Those chapters found that:

  • Since the pandemic, companies have adopted an optimistic but more cautious approach to ongoing research and discovery. That means carefully weighing risks and rewards of capital spending and pipeline expansion while continuously pushing for new and exciting discoveries.
  • Ribonucleic acid (RNA) technologies have catapulted into the spotlight because of COVID. In addition to preventing infectious diseases, these technologies—using non-coding and coding RNA—can be harnessed to treat other conditions, like cancer. When compared to other biologics, RNA technologies have the potential to increase speed to market, lower costs, and reduce regulatory requirements.


Cell therapy development
Cell therapies are expected to evolve into accessible and expected components of patient care.
  • More than 300 of this report’s respondents have cell therapies in their pipelines, creating one of the most dynamic—and challenging—submarkets. Researchers are leveraging standardized platforms to maximize the versatility and scalability of their processes, to where decentralized manufacturing will change the future of autologous production—“a future that will see cell therapies mature from our last line of defense to an accessible and expected level of patient care,” the report predicts.
  • Change is also accelerating for gene therapies. Most respondents said they plan to leap from the small-scale batches necessary for early clinical trials to much larger manufacturing volumes within just three years. Suspension cell cultures, sterile filtration, stable cell lines, and in-house plasmids manufacturing are attracting an enormous volume of R&D activity among both owners and contract manufacturing organizations (CMOs), as this race toward the commercial market heats up.

Modular design will facilitate expansion


Multiple therapies in single buildings
More companies are developing multiple therapies in single buildings.
  • Last year was a milestone year for therapeutic proteins, and not only because the U.S. Food and Drug Administration (FDA) approved the 100th antibody therapy on the market. The field of therapeutic proteins has come a long way—especially in the last few years wherein trends, technologies, and perceptions in the industry saw significant changes. Developers are strategizing for the future.
  • The tailwinds from COVID-19 treatment innovation have unleashed a new era for drug product manufacturing: one that is looking beyond rare disease markets and smaller patient populations to search for the next blockbuster drug; one that is engaging with drug product formulations that are becoming increasingly more complex; and one that readily embraces automation and online/inline monitoring technologies even at the clinical production operations level.


Targeting blockbuster products
Producers are taking bigger swings to develop the next blockbuster drug.
  • CRB’s experts are seeing an “encouraging evolution” in the journey to implementing all aspects of Pharma 4.0—shorthand for efficiencies through process visibility, faster decision making, and real-time system optimization—including smart end-user devices, advanced robotics, and digital twins. “We can see that in the abundance of recent acquisitions that have brought AI innovators into established life science companies,” the report states. But respondents remain sanguine about how to get there, knowing that budget constraints, organizational reluctance, and a lack of skilled labor might hold them back.
  • Most respondents plan to expand over the next five years, with some indicating an intent to establish a footprint in other countries. Optimizing capital and operations expenditure in these expansion efforts means standardizing operations between sites, expediting regulatory approvals, and remaining agile to demand for new modalities and technologies. Hence, CRB concludes, a case for modular design.

Related Stories

Laboratories | Mar 9, 2023

5 laboratory design choices that accelerate scientific discovery

Stephen Blair, director of CannonDesign's Science & Technology Practice, identifies five important design strategies to make the most out of our research laboratories.

University Buildings | Feb 9, 2023

3 ways building design can elevate bold thinking and entrepreneurial cultures

Mehrdad Yazdani of CannonDesign shares how the visionary design of a University of Utah building can be applied to other building types.

Giants 400 | Feb 9, 2023

New Giants 400 download: Get the complete at-a-glance 2022 Giants 400 rankings in Excel

See how your architecture, engineering, or construction firm stacks up against the nation's AEC Giants. For more than 45 years, the editors of Building Design+Construction have surveyed the largest AEC firms in the U.S./Canada to create the annual Giants 400 report. This year, a record 519 firms participated in the Giants 400 report. The final report includes 137 rankings across 25 building sectors and specialty categories.   

University Buildings | Feb 7, 2023

Kansas City University's Center for Medical Education Innovation can adapt to changes in medical curriculum

The Center for Medical Education Innovation (CMEI) at Kansas City University was designed to adapt to changes in medical curriculum and pedagogy. The project program supported the mission of training leaders in osteopathic medicine with a state-of-the-art facility that leverages active-learning and simulation-based training.

Mass Timber | Jan 30, 2023

Net-positive, mass timber building will promote research on planetary well-being in Barcelona

ZGF Architects, along with Barcelona-based firms MIRAG and Double Twist, have designed a net-positive, mass timber center for research on planetary well-being. Located in Barcelona, the Mercat del Peix Research Center will bring together global experts in the experimental sciences, social sciences, and humanities to address challenges related to the future of the planet.

Adaptive Reuse | Dec 21, 2022

University of Pittsburgh reinvents century-old Model-T building as a life sciences research facility

After opening earlier this year, The Assembly recently achieved LEED Gold certification, aligning with the school’s and community’s larger sustainability efforts.

Data Centers | Nov 28, 2022

Data centers are a hot market—don't waste the heat!

SmithGroup's Brian Rener shares a few ways to integrate data centers in mixed-use sites, utilizing waste heat to optimize the energy demands of the buildings.

School Construction | Oct 31, 2022

Claremont McKenna College science center will foster integrated disciplinary research

  The design of the Robert Day Sciences Center at Claremont McKenna College will support “a powerful, multi-disciplinary, computational approach to the grand socio-scientific challenges and opportunities of our time—gene, brain, and climate,” says Hiram E. Chodosh, college president.

Higher Education | Oct 24, 2022

Wellesley College science complex modernizes facility while preserving architectural heritage

A recently completed expansion and renovation of Wellesley College’s science complex yielded a modernized structure for 21st century STEM education while preserving important historical features.

Laboratories | Sep 12, 2022

Lab space scarcity propels construction demand in life sciences sector

In its 2021 Life Sciences Real Estate Outlook, JLL predicted that access to talent would be a primary concern for an industry sector that had been growing by leaps and bounds. A year later, talent still guides real estate decisions. But market conditions of a different sort were cooling the biotech field: namely, investors that have soured on startups which underperformed after going public. What this means for new construction and renovation going forward is unpredictable, as the drivers behind life sciences’ surge are still palpable.

boombox1 - default
boombox2 -
native1 -

More In Category

Giants 400

New Giants 400 download: Get the complete at-a-glance 2022 Giants 400 rankings in Excel

See how your architecture, engineering, or construction firm stacks up against the nation's AEC Giants. For more than 45 years, the editors of Building Design+Construction have surveyed the largest AEC firms in the U.S./Canada to create the annual Giants 400 report. This year, a record 519 firms participated in the Giants 400 report. The final report includes 137 rankings across 25 building sectors and specialty categories.   

halfpage1 -

Most Popular Content

  1. 2021 Giants 400 Report
  2. Top 150 Architecture Firms for 2019
  3. 13 projects that represent the future of affordable housing
  4. Sagrada Familia completion date pushed back due to coronavirus
  5. Top 160 Architecture Firms 2021


Magazine Subscription

Get our Newsletters

Each day, our editors assemble the latest breaking industry news, hottest trends, and most relevant research, delivered to your inbox.


Follow BD+C: